| Primary |
| Multiple Sclerosis |
31.6% |
| Product Used For Unknown Indication |
13.6% |
| Prophylaxis |
9.7% |
| T-cell Lymphoma |
7.6% |
| Chronic Lymphocytic Leukaemia |
5.9% |
| Immunosuppression |
3.4% |
| Depression |
3.3% |
| Antifungal Prophylaxis |
3.3% |
| Antiviral Prophylaxis |
2.5% |
| Infection Prophylaxis |
2.3% |
| Pain |
2.3% |
| Chronic Lymphocytic Leukaemia Recurrent |
1.9% |
| Premedication |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Muscle Spasms |
1.7% |
| Renal Transplant |
1.5% |
| T-cell Prolymphocytic Leukaemia |
1.5% |
| Anxiety |
1.5% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Hypertension |
1.4% |
|
| Suicidal Ideation |
9.5% |
| Hyperthyroidism |
8.2% |
| Thrombocytopenia |
7.3% |
| Pyrexia |
6.9% |
| Breast Cancer |
6.5% |
| Pulmonary Tuberculosis |
6.0% |
| Pleurisy |
5.6% |
| Renal Failure Acute |
5.6% |
| Basedow's Disease |
4.7% |
| Multiple Sclerosis Relapse |
4.7% |
| Cervical Dysplasia |
4.3% |
| Rash |
4.3% |
| Abortion Spontaneous |
3.9% |
| Breast Mass |
3.9% |
| Syncope |
3.4% |
| Transplant Rejection |
3.4% |
| Vomiting |
3.4% |
| Gastroenteritis |
3.0% |
| Gene Mutation |
2.6% |
| Glomerulonephritis Membranous |
2.6% |
|
| Secondary |
| Prophylaxis |
13.4% |
| Multiple Sclerosis |
12.7% |
| Chronic Lymphocytic Leukaemia |
11.9% |
| T-cell Lymphoma |
9.3% |
| Product Used For Unknown Indication |
8.4% |
| Premedication |
7.7% |
| Peripheral T-cell Lymphoma Unspecified |
5.4% |
| Antifungal Prophylaxis |
4.6% |
| Prophylaxis Against Graft Versus Host Disease |
3.5% |
| Stem Cell Transplant |
3.4% |
| Antiviral Prophylaxis |
3.2% |
| Bone Marrow Conditioning Regimen |
2.7% |
| Infection Prophylaxis |
2.5% |
| Depression |
2.2% |
| Acute Myeloid Leukaemia |
1.7% |
| Prophylaxis Against Transplant Rejection |
1.6% |
| Immunosuppression |
1.6% |
| T-cell Prolymphocytic Leukaemia |
1.5% |
| Chronic Lymphocytic Leukaemia Recurrent |
1.4% |
| Muscle Spasms |
1.1% |
|
| Thrombocytopenia |
10.1% |
| Cytomegalovirus Infection |
9.8% |
| Suicidal Ideation |
8.8% |
| Sepsis |
7.0% |
| Vomiting |
6.8% |
| Pyrexia |
6.0% |
| Graft Versus Host Disease |
5.5% |
| Neutropenia |
4.5% |
| Progressive Multifocal Leukoencephalopathy |
4.5% |
| Pancytopenia |
4.3% |
| Hyperthyroidism |
4.0% |
| Transplant Rejection |
4.0% |
| Breast Cancer |
3.8% |
| Basedow's Disease |
3.3% |
| Multiple Sclerosis Relapse |
3.0% |
| Pleurisy |
3.0% |
| Pneumonia |
3.0% |
| Transaminases Increased |
3.0% |
| Febrile Neutropenia |
2.8% |
| Pneumocystis Jiroveci Pneumonia |
2.8% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
13.4% |
| Large Granular Lymphocytosis |
12.4% |
| Stem Cell Transplant |
12.4% |
| Prophylaxis Against Graft Versus Host Disease |
10.0% |
| Product Used For Unknown Indication |
7.2% |
| Antifungal Prophylaxis |
6.8% |
| Prophylaxis |
5.4% |
| Chromosome Analysis Abnormal |
4.7% |
| Chronic Lymphocytic Leukaemia |
4.7% |
| Bone Marrow Conditioning Regimen |
3.4% |
| Graft Versus Host Disease |
3.2% |
| Renal Transplant |
2.9% |
| Immunosuppression |
2.8% |
| Drug Use For Unknown Indication |
1.7% |
| Prophylaxis Against Transplant Rejection |
1.6% |
| T-cell Lymphoma |
1.6% |
| Bone Marrow Transplant |
1.5% |
| Antiviral Prophylaxis |
1.4% |
| Chemotherapy |
1.4% |
| Immunosuppressant Drug Therapy |
1.4% |
|
| Febrile Neutropenia |
13.0% |
| Vomiting |
9.0% |
| Sepsis |
8.0% |
| Therapeutic Response Decreased |
8.0% |
| Thrombocytopenia |
6.0% |
| Pneumonia |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Cystitis Viral |
4.0% |
| Cytomegalovirus Infection |
4.0% |
| Graft Versus Host Disease |
4.0% |
| Neurotoxicity |
4.0% |
| Off Label Use |
4.0% |
| T-cell Lymphoma Recurrent |
4.0% |
| Venoocclusive Disease |
4.0% |
| Adenovirus Infection |
3.0% |
| Convulsion |
3.0% |
| Disease Progression |
3.0% |
| General Physical Health Deterioration |
3.0% |
| Graft Versus Host Disease In Intestine |
3.0% |
| Malignant Neoplasm Progression |
3.0% |
|
| Interacting |
| Cll |
25.0% |
| Drug Use For Unknown Indication |
25.0% |
| Prophylaxis |
25.0% |
| Antifungal Prophylaxis |
8.3% |
| Antiviral Prophylaxis |
8.3% |
| Pneumocystis Carinii Prophylaxis |
8.3% |
|
| Urinary Tract Infection |
100.0% |
|
